Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform
Benzinga
•
•By Globe Newswire
Minovia Therapeutics announced the grant of two new U.S. patents (No. 12,502,408 and No. 12,329,781) covering its proprietary Mitochondrial Augmentation Therapy (MAT) platform for treating primary mitochondrial diseases and renal diseases. The patents, with corresponding grants in Europe and Japan, strengthen the company's intellectual property portfolio. Minovia's lead program MNV-201, currently in clinical trials for Pearson Syndrome, consists of autologous hematopoietic stem cells enriched with placental-derived mitochondria. The company is proceeding with a business combination with Launch One Acquisition Corp., expected to close in the first half of 2026.